+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Factor VIII"

Rare Hemophilia Factors - Global Strategic Business Report - Product Thumbnail Image

Rare Hemophilia Factors - Global Strategic Business Report

  • Report
  • April 2025
  • 93 Pages
  • Global
From
From
Hemophilia A -Pipeline Insight, 2025 - Product Thumbnail Image

Hemophilia A -Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Hemophilia- Pipeline Insight, 2025 - Product Thumbnail Image

Hemophilia- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 250 Pages
  • Global
From
Acquired Hemophilia A - Pipeline Insight, 2025 - Product Thumbnail Image

Acquired Hemophilia A - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 50 Pages
  • Global
From
Von Willebrand's Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Von Willebrand's Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Hemorrhagic Shock - Pipeline Insight, 2025 - Product Thumbnail Image

Hemorrhagic Shock - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Factor IX - Pipeline Insight, 2025 - Product Thumbnail Image

Factor IX - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Factor VIII Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Factor VIII Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Hemophilia A - Epidemiology Forecast - 2034 - Product Thumbnail Image

Hemophilia A - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 144 Pages
  • Global
From
Hemostasis Market - Product Thumbnail Image

Hemostasis Market

  • Report
  • January 2025
  • 250 Pages
  • Global
From
From
From
From
Loading Indicator

The Factor VIII market is a segment of the hematological drugs market, which includes drugs used to treat blood-related disorders. Factor VIII is a protein that helps blood to clot, and is used to treat hemophilia A, a genetic disorder that impairs the body's ability to form blood clots. Factor VIII is typically administered intravenously, and is available in both recombinant and plasma-derived forms. The Factor VIII market is highly competitive, with a number of companies offering products. These include Novo Nordisk, Pfizer, Bayer, CSL Behring, and Shire. Additionally, there are several smaller companies that offer Factor VIII products, such as Octapharma, Kedrion, and Biotest. Show Less Read more